PAX1/JAM3 methylation-a novel biomarker for early detection and accurate management of cervical adenocarcinoma
American Journal of Cancer Research · 2026 · 16 (4) · 1495-1508
DOI: 10.62347/satu5579 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Cancer Research, 2026. Verfasst von Shuxian Feng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, 940th Hospital of The Joint Logistic Support Force of The People's Liberation Army of China Lanzhou, Gansu, China. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecology, 940th Hospital of The Joint Logistic Support Force of The People's Liberation Army of China Lanzhou, Gansu, China.
- Medical Department of Northwest Minzu University Lanzhou, Gansu, China.
Zitieren
APA
Feng, S., Wang, D., He, Q., An, Y., Li, S., & Liu, L. (2026). PAX1/JAM3 methylation-a novel biomarker for early detection and accurate management of cervical adenocarcinoma. American Journal of Cancer Research, 16(4), 1495-1508. https://doi.org/10.62347/satu5579
Vancouver
Feng S, Wang D, He Q, An Y, Li S, Liu L. PAX1/JAM3 methylation-a novel biomarker for early detection and accurate management of cervical adenocarcinoma. American Journal of Cancer Research. 2026;16(4):1495-1508. doi:10.62347/satu5579
BibTeX
@article{Feng2026,
author = {Feng, Shuxian and Wang, Dan and He, Qiannan and An, Yusheng and Li, Sainan and Liu, Ling},
title = {PAX1/JAM3 methylation-a novel biomarker for early detection and accurate management of cervical adenocarcinoma},
journal = {American Journal of Cancer Research},
year = {2026},
volume = {16},
number = {4},
pages = {1495--1508},
doi = {10.62347/satu5579}
}
EUVIMED